Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Sep 15:8:132-143.
doi: 10.1016/j.omtn.2017.06.005. Epub 2017 Jun 12.

Therapeutic miRNA and siRNA: Moving from Bench to Clinic as Next Generation Medicine

Chiranjib Chakraborty  1 , Ashish Ranjan Sharma  2 , Garima Sharma  2 , C George Priya Doss  3 , Sang-Soo Lee  4
Affiliations
Review

Therapeutic miRNA and siRNA: Moving from Bench to Clinic as Next Generation Medicine

Chiranjib Chakraborty et al. Mol Ther Nucleic Acids. .

Abstract

In the past few years, therapeutic microRNA (miRNA) and small interfering RNA (siRNA) are some of the most important biopharmaceuticals that are in commercial space as future medicines. This review summarizes the patents of miRNA- and siRNA-based new drugs, and also provides a snapshot about significant biopharmaceutical companies that are investing for the therapeutic development of miRNA and siRNA molecules. An insightful view about individual siRNA and miRNA drugs has been depicted with their present status, which is gaining attention in the therapeutic landscape. The efforts of the biopharmaceuticals are discussed with the status of their preclinical and/or clinical trials. Here, some of the setbacks have been highlighted during the biopharmaceutical development of miRNA and siRNA as individual therapeutics. Finally, a snapshot is illustrated about pharmacokinetics, pharmacodynamics with absorption, distribution, metabolism, and excretion (ADME), which is the fundamental development process of these therapeutics, as well as the delivery system for miRNA- and siRNA-based drugs.

Keywords: drug development; miRNA; siRNA.

PubMed Disclaimer

Figures

Figure 1
Figure 1
miRNA and siRNA Patents (A) Total number of keyword searches (“microRNA” and “siRNA”) performed in both the US patent search database and the European patent office database. (B) Number of patents in “microRNA” and “siRNA” in case of the different diseases. (C) Number of patents in “microRNA” and “siRNA” in event of the different type of cancers.
Figure 2
Figure 2
List of Biopharmaceutical Companies Involved in miRNA and siRNA Therapeutics Different significant biopharmaceutical companies with their year of establishment since 1983 to 2017 that are involved in the development of the therapeutic miRNA and siRNA molecules.
Figure 3
Figure 3
Status of Various miRNA and siRNA Therapeutics under Clinical Trials (Top left panel) Different siRNA molecules that are in a clinical trial and their status of clinical trial. (Top right panel) Different miRNAs molecules that are in preclinical and/or clinical trial and their status of clinical trial. (Bottom panel) Different important issues related to ADME during development of miRNA- and siRNA-based therapeutics molecules.
See this image and copyright information in PMC

References

    1. Lee R.C., Feinbaum R.L., Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell. 1993;75:843–854. - PubMed
    1. Pasquinelli A.E., Reinhart B.J., Slack F., Martindale M.Q., Kuroda M.I., Maller B., Hayward D.C., Ball E.E., Degnan B., Müller P. Conservation of the sequence and temporal expression of let-7 heterochronic regulatory RNA. Nature. 2000;408:86–89. - PubMed
    1. Reinhart B.J., Slack F.J., Basson M., Pasquinelli A.E., Bettinger J.C., Rougvie A.E., Horvitz H.R., Ruvkun G. The 21-nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegans. Nature. 2000;403:901–906. - PubMed
    1. Calin G.A., Dumitru C.D., Shimizu M., Bichi R., Zupo S., Noch E., Aldler H., Rattan S., Keating M., Rai K. Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc. Natl. Acad. Sci. USA. 2002;99:15524–15529. - PMC - PubMed
    1. Kozomara A., Griffiths-Jones S. miRBase: integrating microRNA annotation and deep-sequencing data. Nucleic Acids Res. 2011;39:D152–D157. - PMC - PubMed